RT Journal Article
T1 Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study.
A1 Albasanz-Puig, Adaia
A1 Gudiol, Carlota
A1 Parody, Rocio
A1 Tebe, Cristian
A1 Akova, Murat
A1 Araos, Rafael
A1 Bote, Anna
A1 Brunel, Anne-Sophie
A1 Calik, Sebnem
A1 Drgona, Lubos
A1 Garcia, Estefania
A1 Hemmati, Philipp
A1 Herrera, Fabian
A1 Ibrahim, Karim Yaqub
A1 Isler, Burcu
A1 Kanj, Souha
A1 Kern, Winfried
A1 Maestro-de-la-Calle, Guillermo
A1 Manzur, Adriana
A1 Marin, Jorge Ivan
A1 Marquez-Gomez, Ignacio
A1 Martin-Davila, Pilar
A1 Mikulska, Malgorzata
A1 Montejo, Jose Miguel
A1 Montero, Milagros
A1 Morales, Hugo Manuel Paz
A1 Morales, Isabel
A1 Novo, Andres
A1 Oltolini, Chiara
A1 Peghin, Maddalena
A1 Del-Pozo, Jose Luis
A1 Puerta-Alcalde, Pedro
A1 Ruiz-Camps, Isabel
A1 Sipahi, Oguz Resat
A1 Tilley, Robert
A1 Yañez, Lucrecia
A1 Gomes, Marisa Zenaide Ribeiro
A1 Carratala, Jordi
K1 Bacteraemia
K1 Bloodstream infection
K1 Multidrug-resistant
K1 Neutropenia
K1 Onco-haematological patients
K1 Pseudomonas aeruginosa
AB Pseudomonas aeruginosa (PA) has historically been one of the major causes of severe sepsis and death among neutropenic cancer patients. There has been a recent increase of multidrug-resistant PA (MDRPA) isolates that may determine a worse prognosis, particularly in immunosuppressed patients. The aim of this study is to establish the impact of antibiotic resistance on the outcome of neutropenic onco-haematological patients with PA bacteraemia, and to identify the risk factors for MDRPA bacteraemia and mortality. This is a retrospective, observational, multicentre, international study. All episodes of PA bacteraemia occurring in neutropenic onco-haematological patients followed up at the participating centres from 1 January 2006 to 31 May 2018 will be retrospectively reviewed. The primary end point will be overall case-fatality rate within 30 days of onset of PA bacteraemia. The secondary end points will be to describe the following: the incidence and risk factors for multidrug-resistant and extremely drug-resistant PA bacteraemia (by comparing the episodes due to susceptible PA with those produced by MDRPA), the efficacy of ceftolozane/tazobactam, the rates of persistent bacteraemia and bacteraemia relapse and the risk factors for very early (48 hours), early (7 days) and overall (30 days) case-fatality rates. The Clinical Research Ethics Committee of Bellvitge University Hospital approved the protocol of the study at the primary site. To protect personal privacy, identifying information of each patient in the electronic database will be encrypted. The processing of the patients' personal data collected in the study will comply with the Spanish Data Protection Act of 1998 and with the European Directive on the privacy of data. All data collected, stored and processed will be anonymised. Results will be reported at conferences and in peer-reviewed publications.
PB BMJ Group
YR 2019
FD 2019-05-24
LK http://hdl.handle.net/10668/14022
UL http://hdl.handle.net/10668/14022
LA en
NO Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, Araos R, et al. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. BMJ Open. 2019 May 24;9(5):e025744
DS RISalud
RD Apr 4, 2025